Price
No data yet.
Social Signal Score
Revenue
$92.10M+25916.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Shannon
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Beta
- 0.85
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.86
Financials
Revenue
$92.10M+25916.9%Net Income
$-31.10MEBITDA
$-21.12MFree Cash Flow
$8.05MEPS (diluted)
$-0.18Shares Outstanding (diluted)
172.82M+8430.1%Operating Expenses
$71.70MCash & Debt
$121.75MReturn of Capital
$191.0KRevenue by Segment (annual)
$332.62MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $291.85M | $554.0K | $0.00 |
| 2024 | $203.07M | $-54.84M | $-0.37 |
| 2023 | $163.91M | $-62.26M | $-0.45 |
| 2022 | $110.25M | $-94.66M | $-0.70 |
| 2021 | $49.59M | $-122.72M | $-1.55 |
| 2020 | $20.43M | $-91.14M | $-2.14 |
| 2019 | $2.72M | $-125.58M | $-3.49 |
| 2018 | $2.46M | $-60.08M | $-4.99 |
| 2017 | $1.56M | $-26.55M | $-13.09 |
| 2016 | $1.07M | $-13.21M | $-7.17 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.01
- Implied price
- $0.09
- Return from $8.74
- -59.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.05 — -99.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -66.4% | -64.9% | -63.6% | -62.4% | -61.4% |
| 3.0% | -64.7% | -63.1% | -61.7% | -60.5% | -59.4% |
| 8.0% | -63.0% | -61.3% | -59.8% | -58.6% | -57.5% |
| 13.0% | -61.3% | -59.5% | -58.0% | -56.7% | -55.5% |
| 18.0% | -59.5% | -57.7% | -56.1% | -54.7% | -53.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (2)
- Newsbusinesswire.com·5h ago·Neutral
Xeris Announces Details for XP-8121 Program Overview Webinar CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company's Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidis…
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $0.02 per share
Typical surprise +38.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.18 vs $0.01miss
- Thu, May 7$0.01 vs $-0.00beat
- Mon, Mar 2$0.06 vs $0.03beat
- Thu, Nov 6$0.00 vs $0.01miss
- Thu, Aug 7$-0.01 vs $-0.03beat
- Thu, May 8$-0.06 vs $-0.07beat
Estimates and results for XERS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XERS officers and directors.
- Bought
- $109k
- Sold
- $6.0m
1 trade
30 trades
- Pieper Stevensold
- Mcculloch Kevinsold
- Hecht Bethsold
- Pieper Stevensold
- Pieper Stevensold
- Mcculloch Kevinsold
- Hecht Bethsold
- Halkuff Dawnsold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.